Investor Overview

Webcast ImageWebcast
AtriCure, Inc. at Morgan Stanley Global Healthcare Conference (Live)
09/18/15 at 10:30 a.m. ET
Webcast ImageWebcast
AtriCure, Inc. at Canaccord 35th Annual Growth Conference  (Replay)
08/12/15 at 1:00 p.m. ET

Corporate Profile

AtriCure was formed by a team with extensive experience in the medical device industry. The company is focused on developing innovative products using proprietary technology that provides doctors alternative, expedient methods to ablate tissue during surgical procedures.

Stock Quote

ATRC (Common)
PriceChange% ChangeVolume
$23.97 - 0.492.00%204,915
Previous CloseToday's OpenIntraday HighIntraday Low
$24.46$24.07$24.49$23.66
Exchange: NASDAQ (US Dollar)
09/01/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Featured Reports

Date
07/28/15
Download Documentation Investor Presentation
07/28/15
Download Documentation Q2 Earnings Call Transcript
04/10/15
Download Documentation 2014 Annual Report
03/24/15
Download Documentation AtriCure Analyst Day Presentation

All Recent News

DateTitle 
08/21/15AtriCure to Present at the Morgan Stanley Global Healthcare Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Aug. 21, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Morgan Stanley Global Healthcare Conference at the Grand Hyatt Hotel in New York City on Friday, September 18, 2015. Management is scheduled to present at 10:30 a.m. Eastern Time. A live audio webcast of the presentation may ... 
Printer Friendly Version
07/28/15AtriCure Reports Second Quarter 2015 Financial Results and Updates 2015 Outlook
Revenue of $32.6 million – up 22.9% as reported, 26.5% constant currency U.S. sales of $25.7 million – up 29.3% International sales of $6.8 million – up 3.5% as reported, 17.9% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 28, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation and left atrial appendage m... 
Printer Friendly Version
07/15/15AtriCure to Present at the Canaccord 35th Annual Growth Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 15, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Canaccord 35th Annual Growth Conference at the Intercontinental Hotel in Boston on Wednesday, August 12, 2015. Management is scheduled to present at 1:00 p.m. Eastern Time. A live audio webcast of the presentation may be ... 
Printer Friendly Version
07/07/15AtriCure to Announce Second Quarter 2015 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 7, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation and left atrial appendage management, will release its financial results for the second quarter of 2015 on Tuesday, July 28, 2015. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, July 28, 2015 to discuss its second quarter 2015 financial results. ... 
Printer Friendly Version
  More News >>

National Recent News

DateTitle 
08/21/15AtriCure to Present at the Morgan Stanley Global Healthcare Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Aug. 21, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Morgan Stanley Global Healthcare Conference at the Grand Hyatt Hotel in New York City on Friday, September 18, 2015. Management is scheduled to present at 10:30 a.m. Eastern Time. A live audio webcast of the presentation may ... 
Printer Friendly Version
07/28/15AtriCure Reports Second Quarter 2015 Financial Results and Updates 2015 Outlook
Revenue of $32.6 million – up 22.9% as reported, 26.5% constant currency U.S. sales of $25.7 million – up 29.3% International sales of $6.8 million – up 3.5% as reported, 17.9% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 28, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation and left atrial appendage m... 
Printer Friendly Version
07/15/15AtriCure to Present at the Canaccord 35th Annual Growth Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 15, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Canaccord 35th Annual Growth Conference at the Intercontinental Hotel in Boston on Wednesday, August 12, 2015. Management is scheduled to present at 1:00 p.m. Eastern Time. A live audio webcast of the presentation may be ... 
Printer Friendly Version
07/07/15AtriCure to Announce Second Quarter 2015 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 7, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation and left atrial appendage management, will release its financial results for the second quarter of 2015 on Tuesday, July 28, 2015. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, July 28, 2015 to discuss its second quarter 2015 financial results. ... 
Printer Friendly Version
  More National News >>

International Recent News

DateTitle 
10/01/13In the Fight Against Atrial Fibrillation, AtriCure Launches Maze IV Training Program in Europe
AMSTERDAM, Netherlands--(BUSINESS WIRE)--Oct. 1, 2013-- AtriCure, Inc. (Nasdaq: ATRC), is partnering with leading atrial fibrillation (Afib) centers and thought leaders across Europe to provide best-in-class training on surgical ablation. The launch of an international Maze IV Training program will take place on October 1 in Germany at Sana Stuttgart Cardiac Surgery Center, one of six initial European hospitals selected to participate in th... 
Printer Friendly Version
06/18/13Promising Mid-Term Results From Thoracoscopic Ablation of Persistent Atrial Fibrillation Presented at Meeting of International Society for Minimally Invasive Cardiothoracic Surgery
Patients show three-year freedom from atrial fibrillation, anti-arrhythmic drugs PRAGUE--(BUSINESS WIRE)--Jun. 18, 2013-- A leading German cardiovascular heart center reported promising mid-term results for the surgical treatment of persistent atrial fibrillation (Afib) during last week’s International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) meeting being held in Prague, Czech Republic. At three-year follow-up, 80 percen... 
Printer Friendly Version
  More International News >>

Company Calendar

DateTitle
09/18/15 
10:30 a.m. ET
AtriCure, Inc. at Morgan Stanley Global Healthcare Conference
  More Events >>

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.